Citations

Clear

3314 citation(s) found for "Do, Alexander".

Focal Nodular Hyperplasia and Focal Nodular Hyperplasia–like Lesions
LeGout, Jordan D. , Bolan, Candice W. , Bowman, Andrew W. , Caserta, Melanie P. , Chen, Frank K. , Cox, Kelly , Sanyal, Rupan , Toskich, Beau B. , Lewis, Jason T., Alexander, Lauren F. , Bowman, Andrew W , Alexander, Lauren F , Toskich, Beau , Lewis, Jason T.

Mayo Clinic

RadioGraphics | June 10, 2022 | Volume: 42 | Issue: 4 | Pages: 1043-1061

10.1148/rg.210156 | PMID 35687520 Get It

Risk of Postoperative Thromboembolism in Men Undergoing Urological Prosthetic Surgery: An Assessment of 21,413 Men
Hebert, Kevin , Matta, Rano , Horns, Joshua J. , Paudel, Niraj, Das, Rupam , Köhler, Tobias , McCormick, Benjamin J. , Hotaling, James M. , Myers, Jeremy B. , Hebert, Kevin J , McCormick, Benjamin J , Myers, Jeremy B , Pastuszak, Alexander W.

Mayo Clinic

Journal of Urology | June 10, 2022 | Volume: 208 | Issue: 4 | Pages: 878-885

10.1097/ju.0000000000002801 | PMID 35686836 Get It

Anatomical Step-by-Step Dissection of Complex Skull Base Approaches for Trainees: Surgical Anatomy of the Endoscopic Endonasal Approach to the Sellar and Parasellar Regions
Agosti, Edoardo , Leonel, Luciano, Gompel, Jamie J. Van , Link, Michael J. , Peris-Celda, Maria, Alexander, A. Yohan , Van Gompel, Jamie J , Agosti, Edoardo , Alexander, A. Yohan, Pinheiro‐Neto, Carlos , Peris‐Celda, Maria

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | June 7, 2022 | Volume: 84 | Issue: 04 | Pages: 361-374

10.1055/a-1869-7532 | PMID 37405244 Get It

Abstract Introduction Surgery of the sellar and parasellar regions can be challenging due to the complexity of neurovascular relationships. The main goal of this study is to develop an educational resource to help trainees understand the pertinent anatomy and procedural steps of the endoscopic endonasal approaches (EEAs) to the sellar and parasellar regions. Methods Ten formalin-fixed latex-injected specimens were dissected. Endoscopic endonasal transsphenoidal transsellar, transtuberculum-transplanum, and transcavernous approaches were performed by a neurosurgery trainee, under supervision from the senior authors and a PhD in anatomy with advanced neuroanatomy experience. Dissections were supplemented with representative case applications. Results Endoscopic endonasal transsphenoidal approaches afford excellent direct access to sellar and parasellar regions. After a wide sphenoidotomy, a limited sellar osteotomy opens the space to sellar region and medial portion of the cavernous sinus. To reach the suprasellar space (infrachiasmatic and suprachiasmatic corridors), a transplanum-prechiasmatic sulcus-transtuberculum adjunct is needed. The transcavernous approach gains access to the contents of the cavernous sinus and both medial (posterior clinoid and interpeduncular cistern) and lateral structures of the retrosellar region. Conclusion The anatomical understanding and technical skills required to confidently remove skull base lesions with EEAs are traditionally gained after years of specialized training. We comprehensively describe EEAs to sellar and parasellar regions for trainees to build knowledge and improve familiarity with these approaches and facilitate comprehension and learning in both the surgical anatomy laboratory and the operating room.
Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study.
Jänne, Pasi A. , Ma, Zhiyong , Salgia, Ravi , Pérez, Casilda Llácer, Curtin, Joshua C. , Roshak, Amy, Schnepp, Robert W. , Thayu, Meena, Knoblauch, Roland E., Krebs, Matthew , Spira, Alexander I. , Cho, Byoung Chul , Besse, Benjamin , Goldman, Jonathan W. , Mansfield, Aaron S. , Minchom, Anna , Ou, Sai‐Hong Ignatius , Wang, Zhijie , Gao, Grace, Lee, Chee Khoon

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: 9008-9008

10.1200/jco.2022.40.16_suppl.9008 Get It

9008 Background: Amivantamab, a fully human bispecific antibody targeting epidermal growth factor receptor (EGFR) and MET, is approved for the treatment of non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion after prior platinum-based chemotherapy. Given its bispecific nature, amivantamab is being explored in patients (pts) with primary MET exon 14 skipping mutation (METex14) in the MET-2 cohort of the CHRYSALIS study. Methods: CHRYSALIS (NCT02609776) is an ongoing phase 1 dose escalation/dose expansion study of amivantamab in pts with advanced NSCLC. Pts with primary METex14 whose disease progressed on or who declined current standard of care therapy were treated with amivantamab 1050 mg (pts <80 kg) or 1400 mg (pts ≥80 kg) weekly in cycle 1 and biweekly thereafter. Response was assessed by investigators using RECIST v1.1. Results: As of 2 Dec 2021, 43 pts with METex14 had received amivantamab. Median age was 70 y (range, 43-88), 58% were women, median prior lines of therapy was 2 (range, 0-10) [eg, crizotinib (n=13), capmatinib (n=11), tepotinib (n=5), anti-MET antibody (n=1)], and 23% had history of brain metastases at baseline. In 36 pts with ≥1 postbaseline disease assessment, median duration of follow-up was 5.8 months (range, 0.3-15.8); 6 pts had no prior treatment, 11 had no prior MET inhibitor, and 19 had a prior MET inhibitor. Overall response rate was 33% (50% [3/6] in treatment-naïve pts, 46% [5/11] in pts with no prior MET inhibitor, and 21% [4/19] in pts with prior MET inhibitor therapy). Clinical benefit rate was >54% regardless of prior treatment (Table). Median duration of response (DOR) was not reached (range, 2.1-12.2 months); 67% (8/13) had DOR ≥6 months. Ten of the 12 responders remain on treatment (6.0-14.4 months) with ongoing responses; 2 discontinued after 2 and 12 months, respectively. Safety profile was consistent with previously reported experience of amivantamab (Sabari 2021 JTO 16(3):S108-109). Treatment-related adverse events leading to dose reduction or discontinuation occurred in 3 pts, each. Conclusions: Amivantamab demonstrates anti-tumor activity in primary METex14 NSCLC including after prior MET inhibitor treatment. Enrollment is ongoing and updated data will be shown. Clinical trial information: NCT02609776. [Table: see text]
KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non–small cell lung cancer (NSCLC) harboring a KRASG12C mutation.
Riely, Gregory J. , Heist, Rebecca S. , Pacheco, Jose M., Sabari, Joshua K. , Leventakos, Konstantinos , Yau, Edwin , Zhang, Jun , Velastegui, Karen , Christensen, James G. , Yan, Xiaohong , Anderes, Kenna , Jänne, Pasi A. , Spira, Alexander I. , Gadgeel, Shirish M. , Ou, Sai‐Hong Ignatius , Johnson, Melissa L. , Bazhenova, Lyudmila , Negrao, Marcelo Vailati , Pennell, Nathan A , Chao, Richard C.

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: 9002-9002

10.1200/jco.2022.40.16_suppl.9002 Get It

9002 Background: KRAS is a key mediator of the RAS/MAPK signaling cascade that promotes cellular growth and proliferation. KRASG12C mutation occurs in ̃14% of NSCLC. Adagrasib, an investigational agent, is a KRASG12C inhibitor that irreversibly and selectively binds KRASG12C, locking it in its inactive state. Adagrasib is optimized for favorable pharmacokinetic (PK) properties, including long half-life (̃24 h), dose-dependent PK, and central nervous system penetration; it has demonstrated objective response and favorable tolerability in the Phase 1/1b setting. Methods: KRYSTAL-1 (NCT03785249) is a multicohort Phase 1/2 study evaluating adagrasib as monotherapy or in combination regimens in patients with advanced solid tumors harboring a KRASG12C mutation. Here we report the first disclosure from all patients enrolled in Cohort A, a Phase 2 cohort with registrational intent, evaluating adagrasib given 600 mg orally BID in patients with NSCLC previously treated with platinum-based chemotherapy and anti-PD-1/L1 therapy. Study objectives include evaluating efficacy (objective response rate [ORR], duration of response [DOR], progression-free survival [PFS], overall survival [OS]), safety, PK, and exploratory correlative analyses. Objective tumor response was assessed per RECIST v1.1 by blinded independent central review (BICR). Results: As of the 15 October 2021 data cutoff, 116 patients with NSCLC harboring a KRASG12C mutation were enrolled and treated, with a median follow-up of 12.5 months. Baseline characteristics include median age 64 years, 65% female, and 15.5%/83.6% with ECOG PS 0/1; 98.3% of patients received adagrasib following prior treatment with immunotherapy and chemotherapy, with a median of 2 prior systemic therapies. The ORR (by BICR) was 42.9% (48/112) and the disease control rate was 79.5% (89/112); 31 patients remain on treatment. Median DOR was 8.5 months (95% CI 6.2–13.8), median PFS was 6.5 months (95% CI 4.7–8.4), median OS was 12.6 months (95% CI 9.2–NE). Treatment-related AEs (TRAEs) of any grade occurred in 97.4% of patients, grade ≥3 TRAEs in 45.7%, 2 grade 5 TRAEs, and 8 (6.9%) TRAEs led to discontinuation. The most commonly reported (≥25%) TRAEs (any grade) were diarrhea (62.9%), nausea (62.1%), vomiting (47.4%), fatigue (40.5%), ALT/AST increased (27.6%/25%), blood creatinine increased (25.9%); the most commonly reported (≥5%) TRAEs (grade 3/4) were lipase increased (6%) and anemia (5.2%). Additional subgroup analyses will be presented, including selected demographics, molecular markers and sites of metastases. Conclusions: Adagrasib is well tolerated and demonstrates promising efficacy in pretreated patients with NSCLC harboring a KRASG12C mutation. A Phase 3 trial evaluating adagrasib monotherapy versus docetaxel in previously treated patients with KRASG12C-mutant NSCLC is ongoing (NCT04685135). Clinical trial information: NCT03785249.
Plasma methylated DNA markers of cutaneous melanoma: Association with PET/CT-positive disease.
Meves, Alexander , Taylor, William R. , Burger, Kelli N. , Quattrocchi, Enrica , Doering, Karen A. , Gonser, Anna M. , Heilberger, Justin, Gysbers, Brianna, Katerov, Viatcheslav E. , Allawi, Hatim T. , Doering, Karen A , Berger, Calise K. , Mahoney, Douglas W. , Cao, Xiaoming , Foote, Patrick H. , Kisiel, John B.

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: 9567-9567

10.1200/jco.2022.40.16_suppl.9567 Get It

9567 Background: Cutaneous melanoma surveillance is important to identify low-volume systemic disease, but imaging is costly and poorly accessible to patients; frequent skin checks lack sensitivity and specificity. We aimed to establish clinical feasibility of a liquid biopsy blood test, which quantifies validated, melanoma-specific, methylated DNA markers (MDMs), previously discovered, and reported by our team, using tissue extracted DNA. Methods: We prospectively collected blood from adult patients with histologically confirmed melanoma metastases and no other internal malignancies (within 5-years) who underwent surveillance by FDG-PET/CT (N = 88). Blood from age- and sex balanced cancer-free controls (N = 100) were compared. From PET/CT, we extracted the number of organs involved, SUV-max, and largest tumor diameter. Unequivocal metastasis was defined as SUV ≥ 4 and largest diameter > 5 mm. Because PET/CT is inadequate for the screening of brain metastases, we excluded the brain from the analysis. MDMs ( chr11.149, HOXA9, chr20.210, FLJ22536, CLIC5, SIX4, chr7.155, chr17.730, chr1.110) were assayed using target enrichment long-probe quantitative-amplified signal assays, normalized to B3GALT6, in blinded fashion. Using a logistic regression approach and nine candidate MDMs, we calculated the sensitivity for detecting patients with metastasis on PET/CT at 100% specificity. Results: 52/88 (59%) of melanoma patients showed evidence of metastasis on PET/CT at the time of blood draw. At 100% specificity, a panel of 4 MDMs ( HOXA9, chr20.210, chr17.730, chr1.110) yielded a sensitivity of 86.5% (45/52 cases) vs. 100 cancer-free controls. When applying this model to the 36 PET/CT-negative patients, specificity was as high as 97.2% (35/36 cases) while maintaining a sensitivity of 86.5% (one patient with a positive test result had a complete metabolic response to binimetinib / encorafenib prior to negative PET/CT). For patients with ≥ 2 organs involved by metastasis, sensitivity was 100% (29/29 cases). False-negative cases had metastasis in single organs and were characterized by minimal tumor burden and oral corticosteroid use. One false-negative patient had localized stage III disease without known primary melanoma. Conclusions: Plasma MDM levels appear highly concordant with FDG-PET/CT in patients with metastatic cutaneous melanoma. A liquid biopsy approach has potential to lower cost and improve patient access to surveillance. Additional prospective studies in larger intended use cohorts are needed to validate our results.
A phase 2 study of VS-6766 (RAF/MEK clamp) RAMP 202, as a single agent and in combination with defactinib (FAK inhibitor) in recurrent KRAS mutant (mt) and BRAF mt non–small cell lung cancer (NSCLC).
Camidge, D. Ross , Jänne, Pasi A. , Rehman, Muneeb, Pachter, Jonathan A. , Patrick, Gloria, Denis, Louis J., Reuss, Joshua E. , Spira, Alexander I. , Patrick, Gloria, Spigel, David R.

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: TPS9147-TPS9147

10.1200/jco.2022.40.16_suppl.tps9147 Get It

TPS9147 Background: KRAS is mutated (mt) in 25% of NSCLC adenocarcinoma, with KRAS G12V and G12C mt occurring in ̃7% and ̃13% of patients (pts), respectively. Whereas G12C inhibitors have demonstrated promising activity in pts with KRAS G12C NSCLC, KRAS G12V NSCLC remains an unmet need. BRAF mt occurs in ̃4% of NSCLC with roughly equal split between BRAF V600E and non-V600E. VS-6766 is a small molecule RAF/MEK clamp that inhibits BRAF, CRAF and MEK, enabling VS-6766 to block MEK signaling without compensatory activation of MEK observed with MEK-only inhibitors. VS-6766 potently inhibits proliferation of KRAS and BRAF mt cell lines. Focal adhesion kinase (FAK) activation is a putative resistance mechanism to RAF and MEK inhibition, and defactinib, a small molecule FAKi, has shown synergistic anti-tumor activity with VS-6766 in KRAS mt NSCLC models. In a KRAS G12V mt NSCLC mouse model, which was shown to be especially dependent on CRAF, VS-6766 induced strong tumor regressions both as monotherapy and in combination with FAKi (Coma AACR 2021). Clinically, VS-6766 monotherapy has shown responses in KRAS mt NSCLC including pts with KRAS G12V and in pts with BRAF V600E solid tumors (Guo 2020; Martinez-Garcia 2012). The combination of VS-6766 + defactinib is currently being evaluated in the Investigator Sponsored FRAME study. In an updated analysis of response in 20 pts with KRAS mt NSCLC, there were 2 confirmed PRs, 1 unconfirmed PR and 10 SDs (ORR = 15%; DCR = 65%) with 7/20 pts remaining on treatment for ≥24 weeks. The 2 pts with KRAS G12V NSCLC both had confirmed PRs (ORR = 100%). This combination regimen exhibited a manageable safety profile with no NSCLC pts discontinuing for adverse events (Krebs AACR 2021). Methods: This is an international phase 2, adaptive, multicenter, randomized, open label study designed to evaluate the efficacy and safety of VS-6766 vs. VS-6766 + defactinib in pts with recurrent KRAS or BRAF mt NSCLC (NCT04620330). Part A will determine the optimal regimen, either VS-6766 monotherapy or VS-6766 + defactinib based on pts with KRAS G12V. Part A will consist of 5 NSCLC arms: Arm 1 VS-6766 monotherapy in KRAS G12V, Arm 2 VS-6766 + defactinib in KRAS G12V, Arm 3 the combination in KRAS non-G12V, Arm 4 the combination in BRAF V600E and Arm 5 the combination in BRAF non-V600E. Part B will determine the efficacy of the optimal regimen identified in Part A. Pts must have histologic or cytologic evidence of NSCLC, measurable disease according to RECIST V1.1, known KRAS or BRAF mt and at least 1 prior systemic therapy (appropriate therapy for activating mutation and/or platinum-based therapy). Part A will enroll 102 pts Arms 1 and 2 (KRAS G12V), and Arms 4 and 5 (BRAF V600E and non-V600E) are currently open. Arm 3 (KRAS non-G12V) enrollment is completed. The total number of pts in Part B will be determined by results from Part A. Clinical trial information: NCT04620330.
The use of artificial intelligence with uncertainty estimation to predict lung cancer relapse from histopathology.
Dolezal, James M. , Kochanny, Sara , Zhu, Annie, Rakshit, Sagar, Bansal, Radhika , Bois, Melanie C. , Bungum, Aaron O., Zhu, Annie, Garassino, Marina Chiara , Bestvina, Christine M. , Mansfield, Aaron S. , Pearson, Alexander T.

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: 8549-8549

10.1200/jco.2022.40.16_suppl.8549 Get It

8549 Background: First-line treatment of early stage non-small cell lung cancer (NSCLC) is surgical resection, but with a 5-year survival of only 54%, rates of future relapse are high. Identifying patients at high risk of relapse can help guide adjuvant treatment decisions. Deep convolutional neural network (DCNN) AI models trained on tumor histology have shown incredible flexibility as potential biomarkers, both in lung cancer and more generally across many malignancies. While DCNN models can obtain extremely accurate results when used for routine purposes such as diagnosis, subtyping, and grading of malignancies, most models trained for prognostication or treatment response prediction do not reach performance sufficient for clinical application. Uncertainty quantification (UQ) – a family of techniques that give DCNN models the ability to report confidence alongside predictions – is an underexplored avenue in cancer AI that may help further improve performance and clinical application of models designed to provide clinicians with estimations of risk. Methods: To explore the potential use of UQ in clinically-oriented DCNN models, we trained models on a single-institution, retrospective digital tumor histology slide cohort from patients with Stage I-III NSCLC who underwent surgical resection to predict risk of future relapse. Estimation of uncertainty was performed using dropout as a Bayesian approximation, and uncertainty thresholds were calculated from training sets using a novel method to identify and remove low-confidence predictions. For comparison, a separate multivariate logistic regression was trained in cross-validation using known clinical risk factors. Results: We trained DCNN models on slides from 198 patients (40 relapsed, 158 without relapse). In this cohort, 130 patients had stage I disease (65.6%), 42 had stage II (21.2%), and 26 had stage III (13.2%). The average age was 69 years, 85% were current or previous smokers, and 38 received guideline-concordant adjuvant chemotherapy. Without UQ, a DCNN model predicted risk of future relapse with an average area under receiver operator curve (AUROC) of 0.74 across three-fold cross-validation. Using UQ estimation, 63% of slides were reported with high confidence. Relapse prediction was significantly improved in the high-confidence cohort, with an average AUROC of 0.83 in cross-validation. With a specificity of 70%, this corresponds to an average sensitivity of 86.8% across the three cross-folds (79.1%, 85.5%, and 95.7%). In comparison, a clinical-only multivariate regression model predicted relapse with a cross-validated AUROC of 0.67. Conclusions: This method of uncertainty quantification appears to be a powerful tool to predict lung cancer recurrence risk from digital histopathology while simultaneously providing clinicians with a measurement of algorithm trustworthiness.
Phase 1b/2 study of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CARTITUDE-1): Two years post-LPI.
Usmani, Saad Zafar, Martin, Thomas , Deol, Abhinav , Htut, Myo, Munshi, Nikhil C. , O’Donnell, Elizabeth , Jackson, Carolyn C. , Yeh, Tzu‐Min, Banerjee, Arnob , Zudaire, Enrique, Zhou, Changwei, Bubuteishvili‐Pacaud, Lida, Usmani, Saad Zafar, Berdeja, Jesús G. , Jakubowiak, Andrzej , Agha, Mounzer , Cohen, Adam D. , Htut, Myo , Lesokhin, Alexander M. , Madduri, Deepu , Lin, Yi , Jagannath, Sundar

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: 8028-8028

10.1200/jco.2022.40.16_suppl.8028 Get It

8028 Background: Ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor T (CAR-T) cell therapy with 2 B-cell maturation antigen (BCMA)–targeting single-domain antibodies, led to early, deep, and durable responses in the phase 1b/2 CARTITUDE-1 study (NCT03548207) in heavily pretreated patients (pts) with relapsed/refractory multiple myeloma (RRMM). At ̃1-year (y) median follow-up (MFU), overall response rate (ORR) was 97%; 67% of pts achieved stringent complete response (sCR). 1-y progression-free survival (PFS) and overall survival (OS) rates were 77% and 89%, respectively (Berdeja 2021). Updated results 2-y post last patient in (LPI) will be presented (̃30-month total MFU). Here, we report CARTITUDE-1 results at 21.7-month MFU. Methods: Eligible pts with RRMM received ≥3 prior lines of therapy (LOT) or were refractory to a proteasome inhibitor (PI) and immunomodulatory drug (IMiD) and had received a PI, IMiD, and anti-CD38 antibody. Bridging therapy was permitted after apheresis. Pts received a single cilta-cel infusion (target dose 0.75×106 CAR+ viable T cells/kg) 5–7 days after lymphodepletion. Primary objectives were to evaluate cilta-cel safety and efficacy. Response was assessed per International Myeloma Working Group criteria by independent review committee and minimal residual disease (MRD) negativity at 10-5 by next-generation sequencing. Results: As of July 22, 2021, 97 pts (59% male; median age 61 y) received cilta-cel. Pts had a median of 6 (range 3–18) prior LOT; 84% were penta-drug exposed, 88% were triple-class refractory, 42% were penta-drug refractory, and 99% were refractory to last LOT. ORR was 97.9% (95% CI 92.7–99.7), 94.9% achieved very good partial response, and 82.5% achieved sCR. Median times to first response, best response, and ≥CR were 1.0, 2.6, and 2.9 months (m), respectively; median duration of response was not reached (NR). Of 61 pts evaluable for MRD, 92% were MRD negative (10-5), sustained for ≥6 m in 44% (27/61) and ≥12 m in 18% (11/61). 2-y PFS was 60.5% (95% CI 48.5–70.4). Median PFS and OS were NR. 2-y PFS rates in pts with sustained MRD negativity for ≥6 m and ≥12 m were 91% and 100%, respectively. There were no new safety signals or new events of CAR-T cell neurotoxicity, movement and neurocognitive treatment-emergent adverse events, or treatment-related deaths since 1-y MFU. 15 second primary malignancies were reported in 11 pts over ̃2-y MFU. Conclusions: At ̃2-y MFU, a single cilta-cel infusion led to deepening and durable responses in heavily pretreated pts with RRMM with a manageable safety profile. Follow-up is ongoing, and landmark 2-y post LPI data (̃8 m additional follow-up; ̃30 m total MFU) will be presented. Further investigations of cilta-cel are ongoing in earlier LOT and outpatient settings across the CARTITUDE program (NCT04133636, NCT04181827, NCT04923893). Clinical trial information: NCT03548207.